First-line osimertinib in advanced EGFR-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohort
G. Suay, S. Cases-Esteban, P. Capdevila, A. García-Márquez, J. Garde-Noguera, P. Espinosa-Olarte, M. Arnal, S. Sandiego-Contreras, F. Aparisi-Aparisi, C. Escoin-Pérez, P. Martín-Martorell, J. García, A. Blasco-Cordellat, S. Blasco-Mollá, J.D. Benítez-Fuentes, C.D. Ávila-Andrade, M. Borregón, O. Juan-Vidal · 2026
Read First-line osimertinib in advanced EGFR-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohort by G. Suay, S. Cases-Esteban, P. Capdevila, A. García-Márquez, J. Garde-Noguera, P. Espinosa-Olarte, M. Arnal, S. Sandiego-Contreras, F. Aparisi-Aparisi, C. Escoin-Pérez, P. Martín-Martorell, J. García, A. Blasco-Cordellat, S. Blasco-Mollá, J.D. Benítez-Fuentes, C.D. Ávila-Andrade, M. Borregón, O. Juan-Vidal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13316214.txt.
Description
G. Suay and a multicenter team report in 2026 real-world results for first-line osimertinib in advanced lung cancer carrying EGFR mutations, treated across eastern Spain. The drug is standard care, yet new upfront combinations are reshaping practice, and how to handle disease that grows in only a few spots remained unclear.
The retrospective cohort measured response rate, real-world progression-free and overall survival, and access to later therapy. Planned checks compared exon 19 deletion with the Leu858Arg change and baseline brain spread. Local ablative therapy for limited progression was a special focus for prolonging drug benefit.
Catalog record
| CREATOR | G. Suay, S. Cases-Esteban, P. Capdevila, A. García-Márquez, J. Garde-Noguera, P. Espinosa-Olarte, M. Arnal, S. Sandiego-Contreras, F. Aparisi-Aparisi, C. Escoin-Pérez, P. Martín-Martorell, J. García, A. Blasco-Cordellat, S. Blasco-Mollá, J.D. Benítez-Fuentes, C.D. Ávila-Andrade, M. Borregón, O. Juan-Vidal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34831 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |